重大事件
即時報告
8-K
2026-06-11
公司專注於開發針對癌症的靶向蛋白降解療法（PROTAC技術）。
AI 繁中摘要
📄 C4 Therapeutics（納斯達克代碼：CCCC）於2026年6月11日提交8-K表格，披露監管FD及其他事件，主要附上公司最新投資者簡報（EX-99.1）及兩份科學海報（EX-99.2、EX-99.3）。
🔬 重點更新：
- 公司專注於開發針對癌症的靶向蛋白降解療法（PROTAC技術）。
- 最新企業簡報（June 2026 Corporate Deck）展示管線進展，包括主要候選藥物CFT1946（BRAF突變腫瘤）及CFT8919（EGFR突變非小細胞肺癌）的臨床數據更新。
- 同時發布兩份科學海報，分別涉及CFT1946與CFT8919的臨床前或早期臨床結果，反映公司在降解劑領域的技術平台實力。
📊 對投資者的潛在影響：
- 8-K本身不包含財務數字，但透過簡報及海報細節，市場可更清楚評估臨床進度及未來里程碑（如數據讀出、監管溝通）。
- 若管線進展正面，或帶動股價波動；反之若出現安全性或療效挑戰，則構成風險。
- 管理層未在8-K中直接發表展望，但簡報通常會暗示未來催化劑（例如啟動關鍵試驗、提交IND等）。
💡 總結：本次申報屬常規資訊更新，重點在於讓投資者同步獲取公司最新臨床及科學進展，建議參閱附件原文以評估具體細節。
展開英文正文
EDGAR Filing Documents for 0001628280-26-042365 SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001628280-26-042365 Filing Date 2026-06-11 Accepted 2026-06-11 07:04:42 Documents 46 Period of Report 2026-06-11 Items Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K cccc-20260611.htm iXBRL 8-K 32366 2 EX-99.1 june2026corporatedeck.htm EX-99.1 43578 3 EX-99.2 finalehaposterpresentati.htm EX-99.2 17873 4 EX-99.3 c4tpr_ehaposterupdatedda.htm EX-99.3 15794 8 c4tpr_ehaposterupdatedda001.jpg GRAPHIC 228884 9 c4tpr_ehaposterupdatedda002.jpg GRAPHIC 200617 10 c4tpr_ehaposterupdatedda003.jpg GRAPHIC 259327 11 c4tpr_ehaposterupdatedda004.jpg GRAPHIC 294459 12 c4tpr_ehaposterupdatedda005.jpg GRAPHIC 139862 13 finalehaposterpresentati001.jpg GRAPHIC 331394 14 june2026corporatedeck001.jpg GRAPHIC 82097 15 june2026corporatedeck002.jpg GRAPHIC 184506 16 june2026corporatedeck003.jpg GRAPHIC 139448 17 june2026corporatedeck004.jpg GRAPHIC 157929 18 june2026corporatedeck005.jpg GRAPHIC 103095 19 june2026corporatedeck006.jpg GRAPHIC 130781 20 june2026corporatedeck007.jpg GRAPHIC 75766 21 june2026corporatedeck008.jpg GRAPHIC 100590 22 june2026corporatedeck009.jpg GRAPHIC 126097 23 june2026corporatedeck010.jpg GRAPHIC 132830 24 june2026corporatedeck011.jpg GRAPHIC 129720 25 june2026corporatedeck012.jpg GRAPHIC 89860 26 june2026corporatedeck013.jpg GRAPHIC 142796 27 june2026corporatedeck014.jpg GRAPHIC 157641 28 june2026corporatedeck015.jpg GRAPHIC 97164 29 june2026corporatedeck016.jpg GRAPHIC 154572 30 june2026corporatedeck017.jpg GRAPHIC 93408 31 june2026corporatedeck018.jpg GRAPHIC 149476 32 june2026corporatedeck019.jpg GRAPHIC 144812 33 june2026corporatedeck020.jpg GRAPHIC 125789 34 june2026corporatedeck021.jpg GRAPHIC 74758 35 june2026corporatedeck022.jpg GRAPHIC 129111 36 june2026corporatedeck023.jpg GRAPHIC 119603 37 june2026corporatedeck024.jpg GRAPHIC 104419 38 june2026corporatedeck025.jpg GRAPHIC 117193 39 june2026corporatedeck026.jpg GRAPHIC 125699 Complete submission text file 0001628280-26-042365.txt 6666645 Data Files Seq Description Document Type Size 5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cccc-20260611.xsd EX-101.SCH 1829 6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cccc-20260611_lab.xml EX-101.LAB 23451 7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cccc-20260611_pre.xml EX-101.PRE 13623 49 EXTRACTED XBRL INSTANCE DOCUMENT cccc-20260611_htm.xml XML 3049 Mailing Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472 Business Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472 (617) 231-0700 C4 Therapeutics, Inc. (Filer) CIK: 0001662579 (see all company filings) EIN.: 475617627 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-39567 | Film No.: 261081424 SIC: 2836 Biological Products, (No Diagnostic Substances) (CF Office: 03 Life Sciences)